Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Jan 30, 2019

SELL
$81.94 - $139.71 $153,063 - $260,978
-1,868 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$152.15 - $192.33 $16,432 - $20,771
108 Added 6.14%
1,868 $301,000
Q4 2017

Feb 08, 2018

SELL
$60.72 - $167.34 $90,108 - $248,332
-1,484 Reduced 45.75%
1,760 $290,000
Q3 2017

Nov 02, 2017

SELL
$61.4 - $88.52 $34,015 - $49,040
-554 Reduced 14.59%
3,244 $202,000
Q2 2017

May 14, 2018

BUY
N/A
363 Added 10.57%
3,798 $302,000
Q1 2017

May 14, 2018

BUY
N/A
3,435
3,435 $244,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Keybank National Association Portfolio

Follow Keybank National Association and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

News

Stay updated on Keybank National Association with notifications on news.